Aldeyra Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
ALDX$0.63+2.9%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets at September 30, 2024 (Unaudited) and December 31, 2023
CONSOLIDATED BALANCE SHEETS
| September 30, | ||
|---|---|---|
| 2024 | December 31, | |
| (unaudited) | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $28,120,029 | $142,823,016 |
| Cash equivalent - reverse repurchase agreements | 40,000,000 | — |
| Marketable securities | 44,624,170 | — |
| Prepaid expenses and other current assets | 3,976,564 | 4,987,317 |
| Total current assets | 116,720,763 | 147,810,333 |
| Deferred offering costs | 267,261 | — |
| Right-of-use assets | 329,968 | 510,814 |
| Fixed assets, net | 1,360 | 5,764 |
| Total assets | $117,319,352 | $148,326,911 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $186,919 | $1,338,057 |
| Accrued expenses | 10,423,297 | 5,536,464 |
| Current portion of debt | 279,957 | 15,146,546 |
| Operating lease liabilities | 263,241 | 239,183 |
| Deferred collaboration revenue | 6,000,000 | — |
| Total current liabilities | 17,153,414 | 22,260,250 |
| Deferred collaboration revenue, long-term | — | 6,000,000 |
| Operating lease liabilities, long-term | 70,234 | 271,631 |
| Long-term debt, net of current portion | 15,000,000 | — |
| Total liabilities | 32,223,648 | 28,531,881 |
| Commitments and contingencies (Notes 3, 9, & 14) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding | — | — |
| Common stock, $0.001 par value; 150,000,000 authorized and 59,549,598 and 59,195,951 shares issued and outstanding, respectively | 59,550 | 59,196 |
| Additional paid-in capital | 519,271,439 | 513,994,982 |
| Accumulated other comprehensive income | 66,540 | — |
| Accumulated deficit | (434,301,825) | (394,259,148) |
| Total stockholders’ equity | 85,095,704 | 119,795,030 |
| Total liabilities and stockholders’ equity | $117,319,352 | $148,326,911 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.